Inovio Pharma

INO NASDAQ
2.790
-0.090
-3.13%
After Hours: 2.760 -0.03 -1.08% 19:39 07/19 EDT
Open
2.860
Prev Close
2.880
High
2.945
Low
2.790
Volume
743.98K
Avg Vol (3M)
1.06M
52 Week High
6.30
52 Week Low
2.150
% Turnover
0.76%
Market Cap
273.51M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Inovio Pharma INO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
MORE >

Recently

Name
Price
%Change